CompletedNCT05416892Updated Jun 14, 2022

What is the Impact of Implementing Pharmaceutical Algorithms in the PharmaClass® Software, on the Handling the Patient's Medication Load, by the Clinical Pharmacist?

An observational study in Pharmacist-Patient Relations, sponsored by Murielle Surquin. Completed at 1 site in Belgium. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2022-06-14.

Sponsored by Murielle Surquin · Observational

Study type: Observational
Model: Cohort
Time perspective: Prospective
Enrollment: 109
Ages: 75 Years and older
Sex: All

Study summary

The clinical pharmacists present in the hospitalisation units aim to ensure the daily review of the drug prescriptions of hospitalized patients.

In order to optimize their work, the objective of this study would be to provide them with a clinical decision support tool via artificial intelligence in order to improve the patient's medication management. This study will test the Pharmaclass® software.

Conditions studied

Pharmacist-Patient Relations

In context

Lead sponsor

Murielle Surquin is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 75 Years and older
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Non-probability sample

Study population

Hospitalized patient entering the SU06 or SU13 geriatrics unit of the Paul Brien site of the CHU Brugmann Hospital between November 16 2021 and April 15, 2022

Inclusion criteria

Hospitalized patient entering the SU06 or SU13 geriatrics unit of the Paul Brien site of the CHU Brugmann Hospital between November 16 2021 and April 15, 2022
Speaking French and/or Dutch
With chronic renal failure or taking at least one medicine for diabetes, heart, COPD, asthma, high blood pressure, epilepsy, atrial fibrillation, osteoporosis, high cholesterol, pain, parkinsonism, blood clotting, constipation, thyroid, depression, benign prostatic hypertrophy, gastric ulcer, Alzheimer's disease, cirrhosis as well as for electrolyte disorders (hypo or hypernatremia / potassium / calcium/magnesemia/phosphatemia).

Exclusion criteria

Exclusion Criteria:

Patient who died or was transferred to another care unit during his/her hospitalization

Study design

Observational model: Cohort
Time perspective: Prospective
Enrollment: 109 participants (actual)
Patient registry: No

Groups and cohorts

Patients of Geriatric Wards SU06 and SU13 of the CHU Brugmann Hospital
Other: Pharmaclass® software

Interventions

OtherPharmaclass® software
Clinical decision support tool via artificial intelligence in order to improve the patient's medication management.

What researchers measure

Primary outcomes

Time
Time required to perform an intervention (pharmacist versus software)
Time frame: 5 months
Dosage compliance
Dosage compliance with existing recommendations and laboratory results/clinical parameters (pharmacist versus software)
Time frame: 5 months
Medication error severity
Severity of the medication error that could be avoided (pharmacist versus software)
Time frame: 5 months
Geriatrician approval
Number of interventions validated/refused by the geriatrician (pharmacist versus software)
Time frame: 5 months

Study locations

1 site

Brugmann university hospital
Brussels, 1020, Belgium

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Jun 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT05416892
Lead sponsor: Murielle Surquin
Responsible party: Murielle Surquin (Head of Geriatry Department, Brugmann University Hospital) — Sponsor-investigator
First posted: Jun 14, 2022
Start date: Sep 14, 2021
Primary completion: Apr 1, 2022
Completion: Apr 1, 2022
Last update: Jun 14, 2022

Study contacts

Charline DANNEEL

principal investigator · CHU Brugmann

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Murielle Surquin

Start the discussion